Xplico named “a 2016 Gazelle Company” (a growth company) by the leading Danish business newspaper Boersen.

By |January, 2017|

We are delighted that the leading Danish business newspaper Børsen has named Xplico a 2016 Gazelle Company. Børsen analyses every year all the Danish companies to identify growth companies named Gazelle companies. A Gazelle company […]

Xplico is pleased to announce that Peter Abelin has joined our valuation team.

By |January, 2017|

Xplico is pleased to announce that Peter Abelin has joined our valuation team.
Peter has more than 25 years’ experience from the life science industry working with equity portfolio management, financial research and pharmaceutical development […]

Xplico launchs Xplico Captable – a cap table providing simulations and waterfall analysis of the various stakeholders’ investments and values in a company.

By |January, 2017|

Xplico Captable is a capitalization table providing simulations and waterfall analysis of the founders’ and investors’ percentage of ownership, equity dilution, and value of equity in connection with (potential) funding rounds and exits. Xplico Captable […]

BIO-Europe Spring 2017

By |November, 2016|

BIO-Europe Spring 2017, Barcelona, Spain, March 20 – 22, 2017

Please meet us at BIO-Europe Spring Partnering Conference in Barcelona Spain. BIO-Europe Spring is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe, and continues the […]

Deal supported by Xplico

By |October, 2016|

PharmaMar and Boryung Pharm sign a licensing agreement for Aplidin® (plitidepsin) in Korea.

Deal supported by Xplico

By |October, 2016|

Nuevolution Announces Strategic Collaboration with Amgen in Oncology and Neuroscience.

Deal supported by Xplico

By |October, 2016|

Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy.

Deal supported by Xplico

By |October, 2016|

TRACON Pharmaceuticals Announces a Strategic Licensing Collaboration for Two Janssen Oncology Assets and a $5 Million Equity Investment from Johnson & Johnson Innovation – JJDC, Inc.

BIO International Convention

By |October, 2016|

2017 BIO International Convention, San Diego, USA, June 19-22, 2017

Please meet us at the 2016 BIO International Convention in San Francisco, USA. The BIO International Convention is the largest global event for the biotechnology industry […]

Spin-out supported by Xplico

By |September, 2016|

4SC sells immunology portfolio to Immunic